Bicycle Financial Statements From 2010 to 2025

BCYC Stock  USD 9.98  0.29  2.99%   
Bicycle Therapeutics financial statements provide useful quarterly and yearly information to potential Bicycle Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bicycle Therapeutics financial statements helps investors assess Bicycle Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bicycle Therapeutics' valuation are summarized below:
Gross Profit
-137.7 M
Market Capitalization
670.6 M
Enterprise Value Revenue
21.2178
Revenue
35.3 M
Earnings Share
(2.90)
We have found one hundred twenty available fundamental signals for Bicycle Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of Bicycle Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of March 18, 2025, Market Cap is expected to decline to about 559.2 M. In addition to that, Enterprise Value is expected to decline to about 138.5 M

Bicycle Therapeutics Total Revenue

37.04 Million

Check Bicycle Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicycle Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 36 M, Discontinued Operations of 0.0 or Interest Expense of 1.9 M, as well as many indicators such as Price To Sales Ratio of 243, Dividend Yield of 0.0 or PTB Ratio of 5.52. Bicycle financial statements analysis is a perfect complement when working with Bicycle Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Bicycle Therapeutics Correlation against competitors.
For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.

Bicycle Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsB956.9 M247.3 M
Slightly volatile
Other Current Liabilities43.3 M41.2 M10.6 M
Slightly volatile
Total Current Liabilities34.3 M67.2 M21.1 M
Slightly volatile
Accounts Payable16.6 M15.8 M4.7 M
Slightly volatile
Cash923.5 M879.5 M220.8 M
Slightly volatile
Other Assets10.2 M9.7 M3.1 M
Slightly volatile
Cash And Short Term Investments923.5 M879.5 M220.8 M
Slightly volatile
Net Receivables37.4 M35.7 M11 M
Slightly volatile
Capital Surpluse235.5 M224.3 M90 M
Slightly volatile
Total Liabilities124.8 M163.8 M73 M
Slightly volatile
Total Current Assets975 M928.6 M236.3 M
Slightly volatile
Common Stock934.5 K890 K229.7 K
Slightly volatile
Property Plant Equipment39.6 M37.7 M11 M
Slightly volatile
Property Plant And Equipment Net14.7 M17.2 M8.2 M
Slightly volatile
Current Deferred Revenue12.3 M10.2 M8.1 M
Slightly volatile
Non Current Assets Total19.7 M28.3 M11.3 M
Slightly volatile
Non Currrent Assets Other11.6 M11.1 M3.5 M
Slightly volatile
Common Stock Shares Outstanding611.2 M582.1 M89.6 M
Slightly volatile
Liabilities And Stockholders EquityB956.9 M274.5 M
Slightly volatile
Non Current Liabilities Total101.8 M96.6 M101.5 M
Pretty Stable
Property Plant And Equipment Gross20.8 M36.1 M11.4 M
Slightly volatile
Non Current Liabilities Other1.1 M1.1 M1.4 M
Slightly volatile
Net Working Capital904.4 M861.4 M236.8 M
Slightly volatile
Capital Stock934.5 K890 K233 K
Slightly volatile
Short and Long Term Debt Total3.8 MM11 M
Slightly volatile
Capital Lease Obligations10.2 M9.5 M5.2 M
Slightly volatile

Bicycle Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income36 M34.3 M5.7 M
Slightly volatile
Selling General Administrative75.8 M72.2 M23.4 M
Slightly volatile
Cost Of Revenue7.1 M7.4 M14.3 M
Pretty Stable
Total Operating Expenses257.4 M245.1 M73.3 M
Slightly volatile
Depreciation And Amortization7.5 M7.2 MM
Slightly volatile
Reconciled Depreciation7.5 M7.2 MM
Slightly volatile

Bicycle Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock43.8 M67.2 M37.8 M
Slightly volatile
Depreciation7.5 M7.2 MM
Slightly volatile
Capital Expenditures1.2 M1.2 M2.1 M
Slightly volatile
Total Cash From Financing Activities545.7 M519.8 M122.8 M
Slightly volatile
End Period Cash Flow924.1 M880.1 M220.9 M
Slightly volatile
Change To Netincome26.9 M25.6 MM
Slightly volatile
Stock Based Compensation40 M38.1 M10.3 M
Slightly volatile
Begin Period Cash Flow553.3 M527 M143.3 M
Slightly volatile
Issuance Of Capital Stock571.3 M544.1 M126 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio24323185.6899
Slightly volatile
Days Sales Outstanding469369475
Slightly volatile
Stock Based Compensation To Revenue0.641.07950.5501
Slightly volatile
Capex To Depreciation0.160.17211.3294
Very volatile
EV To Sales21620659.9028
Slightly volatile
Days Of Inventory On Hand1.0E-41.0E-46.0E-4
Slightly volatile
Payables Turnover0.420.454.5979
Pretty Stable
Sales General And Administrative To Revenue1.862.04622.6378
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue3.394.90344.8504
Slightly volatile
Capex To Revenue0.03330.0350.3987
Slightly volatile
Cash Per Share1.441.5114.7312
Slightly volatile
Days Payables Outstanding5638471.3 K
Slightly volatile
Income Quality0.690.97450.7118
Pretty Stable
Net Debt To EBITDA2.665.30972.3076
Slightly volatile
Current Ratio7.0313.81246.4959
Slightly volatile
Receivables Turnover0.780.98940.8325
Slightly volatile
Debt To Equity0.00480.0050.0494
Slightly volatile
Capex Per Share0.0020.00210.08
Slightly volatile
Average Receivables1.7 MM2.1 M
Slightly volatile
Revenue Per Share0.05760.06060.3374
Slightly volatile
Interest Debt Per Share0.00930.00980.4643
Slightly volatile
Debt To Assets0.0040.00420.0346
Slightly volatile
Operating Cycle304369232
Slightly volatile
Days Of Payables Outstanding5638471.3 K
Slightly volatile
Ebt Per Ebit1.10.82811.0069
Very volatile
Long Term Debt To Capitalization0.110.08790.1191
Slightly volatile
Total Debt To Capitalization0.00480.0050.0445
Slightly volatile
Debt Equity Ratio0.00480.0050.0494
Slightly volatile
Quick Ratio7.0313.81246.4959
Slightly volatile
Net Income Per E B T1.090.97260.9988
Pretty Stable
Cash Ratio13.7413.08236.2941
Slightly volatile
Days Of Inventory Outstanding1.0E-41.0E-46.0E-4
Slightly volatile
Days Of Sales Outstanding469369475
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.261.00751.1112
Pretty Stable
Fixed Asset Turnover2.152.05221.7722
Very volatile
Debt Ratio0.0040.00420.0346
Slightly volatile
Price Sales Ratio24323185.6899
Slightly volatile
Asset Turnover0.06140.03690.0439
Slightly volatile

Bicycle Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap559.2 M579.2 M348.2 M
Slightly volatile
Enterprise Value138.5 M145.8 M157.7 M
Slightly volatile

Bicycle Fundamental Market Drivers

Cash And Short Term Investments879.5 M

Bicycle Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bicycle Therapeutics Financial Statements

Bicycle Therapeutics stakeholders use historical fundamental indicators, such as Bicycle Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Bicycle Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bicycle Therapeutics' assets and liabilities are reflected in the revenues and expenses on Bicycle Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bicycle Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue10.2 M12.3 M
Total Revenue35.3 M37 M
Cost Of Revenue7.4 M7.1 M
Stock Based Compensation To Revenue 1.08  0.64 
Sales General And Administrative To Revenue 2.05  1.86 
Research And Ddevelopement To Revenue 4.90  3.39 
Capex To Revenue 0.04  0.03 
Revenue Per Share 0.06  0.06 
Ebit Per Revenue(5.95)(6.25)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Bicycle Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bicycle Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bicycle Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bicycle Therapeutics Stock:
Check out the analysis of Bicycle Therapeutics Correlation against competitors.
For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicycle Therapeutics. If investors know Bicycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicycle Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.90)
Revenue Per Share
0.606
Quarterly Revenue Growth
(0.30)
Return On Assets
(0.17)
Return On Equity
(0.29)
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bicycle Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicycle Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicycle Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.